antipsychotics

Loxapine succinate (Loxapac), a D2DR and D4DR inhibitor, is utilized in schizophrenia.

Tenilapine is a neuroleptic compound that can be used to study atypical antipsychotics.

Zuclopenthixol (cis-Clopenthixol) is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

Opromazine hydrochloride belongs to the phenothiazine class of antipsychotics and reduces the activity of dopaminergic pathways by blocking dopamine receptors in the brain. It is mainly used for the treatment of psychiatric disorders such as schizophrenia and psychosis.

Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

Compound (−)-19, also known as (-)-5-HT2C agonist-3, is a selective 5-HT2C agonist exhibiting a preference for Gq signaling. It demonstrates efficiency with EC50 values for 5-HT2 receptor subtypes as follows: 5-HT2C at 103 nM, 5-HT2B at 570 nM, and 5-HT2A at 72 nM. This compound is utilized in research on antipsychotics.

Loxapine is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent,used primarily in the treatment of schizophrenia. The drug is a member of the dibenzoxazepine class and structurally related to clozapine (which belongs to the chemically akin class of dibenzodiazepines).

Clopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

EMD-23448 is a dopamine autoreceptor agonist as potential antipsychotics.

alpha-Clopenthixol dihydrochloride is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

Clopenthixol decanoate is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.

Blonanserin-d5 is a deuterated compound of Blonanserin. Blonanserin has a CAS number of 132810-10-7. Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.